CVCarla Bianca Luena Victorio

Carla Bianca Luena Victorio

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Carla Bianca Luena Victorio has a total of 52 co-authors. Here are the top co-authors by number of shared publications:

  • Ann-Marie Chacko

    Laboratory for Translational and Molecular Imaging, Cancer and Stem Cell Biology Programme, Duke-NUS Medical School Singapore. 8 College Road Singapore 169857

    8 shared publications
  • Arun Ganasarajah

    Duke-NUS Medical School, Singapore

    6 shared publications
  • Kaw Bing Chua

    Natl Univ Singapore, Temasek Lifesci Lab, 1 Res Link, Singapore 117604, Singapore

    6 shared publications
  • Yishi Xu

    Temasek Life Sciences Laboratory, 1 Research Link, National University of Singapore, Singapore, 117604, Singapore

    6 shared publications
  • Joanne Ong

    Laboratory for Translational and Molecular Imaging, Cancer and Stem Cell Biology Programme, Duke-NUS Medical School Singapore. 8 College Road Singapore 169857

    5 shared publications
  • Qimei Ng

    Temasek Lifesciences Laboratory, 1 Research Link, National University of Singapore, Singapore

    5 shared publications

Latest Publications

  • Open Access

    Lung [ 18 F]FDG-PET is an early pharmacodynamic biomarker of antiviral efficacy in preclinical influenza

    by Carla Bianca Luena Victorio, Arun Ganasarajah, Shantanu Gupta, Joanne Ong, Ann-Marie Chacko

    Background: Influenza remains a major cause of global morbidity and mortality. Pharmacodynamic biomarkers that quantify treatment response within the lung could accelerate influenza therapeutic development. We evaluated [¹ F]fluorodeoxyglucose positron emission tomography ([ 18 F]FDG-PET) as a non-invasive biomarker of antiviral efficacy. Methods: Serial [ 18 F]FDG-PET was evaluated in two murine H1N1 influenza models using mouse-adapted PR8 strain and CA-09 clinical isolate following treatment with favipiravir, baloxavir marboxil, or ribavirin. PET measures were compared with pulmonary viral burden, inflammatory cytokine expression, computed tomography (CT) imaging, and respiratory function measured by whole-body plethysmography (WBP). Results: Antiviral treatment in PR8 infection model reduced lung [ 18 F]FDG uptake by 27–49% and metabolic lung volume (MLV) by 40.5–74.6% (both p < 0.001). Antiviral response was detectable as early as 3 days post-infection, when uptake decreased by 28.7–53.2% and MLV by 33.8–75.0%. Lung [ 18 F]FDG uptake also strongly correlated with MLV ( r = 0.93, p < 0.001) and with pulmonary viral burden and inflammatory mediators. These findings were reproduced in a model of pandemic H1N1/CA-09, where baloxavir reduced uptake by 37.4% ( p = 0.02) and MLV by 67.5% ( p < 0.001) at day 3. In both models, changes in [ 18 F]FDG-PET parameters preceded improvements in lung CT and respiratory function. Conclusions: Lung [ 18 F]FDG-PET provides an early, quantitative measure of antiviral response in experimental influenza, supporting its further evaluation as a translational pharmacodynamic endpoint.

  • Open Access

    Functional antibody responses and protection against symptomatic dengue

    by Caroline Lin Lin Chua, Hoa Thi My Vo, Carla Bianca Luena Victorio, Vinit Upasani, Bryan Ju Min Yap, Andrew Teo

    Exposure to dengue virus (DENV) triggers the development of anti-viral antibodies that may contribute to either protection or disease progression. Antibodies exist in different isotypes and subtypes, with diverse specificities and functions. IgG antibodies are produced during primary and secondary DENV infections, where they play a role central role in mediating protective immunity, and may also contribute to antibody-dependent enhancement in a secondary heterotypic infection. Although IgG antibodies are widely recognised as key mediators of protective immune responses during DENV infection, antibody specificities, types and functions that reliably correlate with protection remain unclear. A better understanding of anti-DENV antibodies and their roles in protection against symptomatic dengue is essential especially in guiding the design of dengue vaccines. In this review, antibody functions and effector mechanisms in DENV infection are discussed, with a focus on naturally acquired immunity and neutralising antibody responses following vaccination. In addition, current knowledge gaps in antibody functions during DENV infection will be highlighted.


  • Open Access

    Myeloperoxidase (MPO) exacerbates dengue-associated liver injury and contributes to disease pathogenesis in mouse models

    by Carla Bianca Luena Victorio, Andrew Teo, Shantanu Gupta, Arun Ganasarajah, Joanne L Ong, Jasmine Sk, Kissila Rabelo, Luciana Lontro Alves, Carlos Alberto Basilio-De-Oliveira, Rodrigo Panno Basilio-De-Oliveira, et al.

    Severe dengue can damage the liver through unestablished mechanisms. We investigated the role of myeloperoxidase (MPO), a neutrophil enzyme, in dengue through patients, fatal liver samples, and mouse infection models. Observations from two independent clinical cohorts revealed elevated plasma MPO levels in dengue and, in one cohort, MPO was further linked to liver injury markers during the critical phase of disease, whereas livers from dengue fatal cases revealed MPO build-up in the vicinity of CD177+ activated neutrophils. In mice, dengue led to MPO overexpression, oxidative damage, and broad activation of innate and systemic inflammatory pathways in livers. Blocking MPO activity alleviated these and improved survival in one model and delayed disease progression without preventing death in another. These findings establish MPO as a functional mediator of severe dengue-associated liver injury and inflammation, which warrants further preclinical investigation into its hepatic pathogenic mechanism and its validity as target for therapeutic intervention.

  • Open Access

    Nanoluciferase reporter preserves immunocompetent glioma model fidelity while facilitating longitudinal molecular imaging

    by Carla Bianca L Victorio, Wisna Novera, Arun Ganasarajah, Joanne L Ong, Shantanu Gupta, Eng Eong Ooi, Sven Petersen, Rasha Msallam, Ann-Marie Chacko

    Glioblastoma studies employ syngeneic orthotopic models to preserve tumor-immune interactions, but intracranial tumor burden is challenging to monitor longitudinally. Bioluminescence imaging enables non-invasive assessment, although reporter immunogenicity may compromise model fidelity. We engineered murine GL261 glioma cells to stably express nanoluciferase (NLuc) and compared them with parental GL261 (WT) and GL261 cells expressing red-shifted firefly luciferase (Red-FLuc). In vitro, GL261-NLuc retained growth kinetics and morphology comparable to GL261-WT and produced >100-fold stronger bioluminescence than GL261-Red-FLuc. In immunocompetent mice, GL261-NLuc formed lethal brain tumors with survival and tumor histopathology, immune profile, and response patterns to experimental oncolytic virus therapy broadly resembling GL261-WT. In contrast, GL261-Red-FLuc tumors regressed and exhibited heightened inflammation and increased infiltration of activated CD8+ T-cells. Longitudinal imaging of GL261-NLuc tumors detected treatment-associated changes in growth kinetics not captured by survival alone. These establish GL261-NLuc as a practical reporter for longitudinal immunocompetent glioblastoma studies amenable to immunotherapy evaluations.

  • Open Access

    Validation of Lung [18F]FDG Uptake as a Quantitative PET Biomarker for Influenza-Associated Pulmonary Inflammation

    by Carla Bianca Luena Victorio, Shantanu Gupta, Arun Ganasarajah, Joanne Ong, Ann-Marie Chacko

    Purpose: Influenza (flu) is a respiratory illness caused by lung infection with influenza viruses. This study establishes lung [ 18 F]FDG uptake by PET/CT as an accurate measure of lung inflammation associated with influenza A virus (IAV) H1N1 infection. Procedures: Immunocompetent BALB/c mice were infected with a highly lethal dose of influenza A virus (PR8 strain) and intravenously injected with [ 18 F]FDG. Ex vivo tissue biodistribution was assessed by gamma counting, while in vivo tissue biodistribution was analyzed by VOI analysis of PET/CT images. Disease severity was also investigated by VOI measurements of high-resolution lung CT images. Infection and inflammation were confirmed by immunohistochemical staining; while viral replication and expression of inflammatory proteins (cytokines and chemokines) were measured in lung tissues by qRT-PCR and multiplex ELISA, respectively. Results: Ex vivo tissue biodistribution of [ 18 F]FDG revealed that the lungs were the only relevant imaging target in influenza-infected mice. Lung [ 18 F]FDG uptake on PET/CT images increased with disease severity and exhibited 1.53-fold increase on day 1 and up to 2.63-fold increase on day 6 post-infection compared to pre-infection levels. Lung uptake correlated with the increased production of pro-inflammatory proteins associated with influenza infection. Conclusions: Lung [ 18 F]FDG uptake on PET images is a non-invasive molecular biomarker of influenza-A virus-induced lung inflammation and disease, effectively distinguishing infected from non-infected lungs as early as day 1 post-infection.


  • Open Access

    Translocator protein (TSPO) is a biomarker of Zika virus (ZIKV) infection-associated neuroinflammation

    by Carla Bianca Luena Victorio, Arun Ganasarajah, Wisna Novera, Joanne Ong, Rasha Msallam, Ann-Marie Chacko

    Zika is a systemic inflammatory disease caused by infection with Zika virus (ZIKV). ZIKV infection in adults is associated with encephalitis marked by elevated expression of pro-inflammatory cytokines and chemokines, as well as increased brain infiltration of immune cells. In this study, we demonstrate that ZIKV encephalitis in a mouse infection model exhibits increased brain TSPO expression. TSPO expression on brain-resident and infiltrating immune cells in ZIKV infection correlates with disease and inflammation status in the brain. Brain TSPO expression can also be sensitively detected ex vivo and in vitro using radioactive small molecule probes that specifically bind to TSPO, such as [3H]PK11195. TSPO expression on brain-resident and infiltrating immune cells is a biomarker of ZIKV neuroinflammation, which can also be a general biomarker of acute viral neuroinflammatory disease.


  • Open Access

    Repurposing of Zika virus live-attenuated vaccine (ZIKV-LAV) strains as oncolytic viruses targeting human glioblastoma multiforme cells

    by Carla Bianca Luena Victorio, Wisna Novera, Arun Ganasarajah, Joanne Ong, Melisyaa Thomas, Jonas Wu, Hilary Si Yin Toh, Alfred Xuyang Sun, Eng Eong Ooi, Ann-Marie Chacko

    Glioblastoma multiforme (GBM) is the most common malignant primary brain cancer affecting the adult population. Median overall survival for GBM patients is poor (15 months), primarily due to high rates of tumour recurrence and the paucity of treatment options. Oncolytic virotherapy is a promising treatment alternative for GBM patients, where engineered viruses selectively infect and eradicate cancer cells by inducing cell lysis and eliciting robust anti-tumour immune response. In this study, we evaluated the oncolytic potency of live-attenuated vaccine strains of Zika virus (ZIKV-LAV) against human GBM cells in vitro. Our findings revealed that Axl and integrin αvβ5 function as cellular receptors mediating ZIKV-LAV infection in GBM cells. ZIKV-LAV strains productively infected and lysed human GBM cells but not primary endothelia and terminally differentiated neurons. Upon infection, ZIKV-LAV mediated GBM cell death via apoptosis and pyroptosis. This is the first in-depth molecular dissection of how oncolytic ZIKV infects and induces death in tumour cells.


  • Open Access

    TSPO expression in a Zika virus murine infection model as an imaging target for acute infection-induced neuroinflammation

    by Carla Bianca Luena Victorio, Rasha Msallam, Wisna Novera, Joanne Ong, Tham Jing Yang, Arun Ganasarajah, Jenny Low, Satoru Watanabe, Ann-Marie Chacko

    Introduction: Zika virus (ZIKV) is a neurotropic human pathogen that causes neuroinflammation, whose hallmark is elevated translocator protein (TSPO) expression in the brain. This study investigates ZIKV-associated changes in adult brain TSPO expression, evaluates the effectiveness of TSPO radioligands in detecting TSPO expression, and identifies cells that drive brain TSPO expression in a mouse infection model. Methods: The interferon-deficient AG129 mouse infected with ZIKV was used as neuroinflammation model. TSPO expression was evaluated by tissue immunostaining. TSPO radioligands, [3H]PK11195 and [18F]FEPPA, were used for in vitro and ex vivo detection of TSPO in infected brains. [18F]FEPPA-PET was used for in vivo detection of TSPO expression. Cell subsets that contribute to TSPO expression were identified by flow cytometry. Results: Brain TSPO expression increased with ZIKV disease severity. This increase was contributed by TSPO-positive microglia and infiltrating monocytes; and by influx of TSPO-expressing immune cells into the brain. [3H]PK11195 and [18F]FEPPA distinguish ZIKV-infected brains from normal controls in vitro and ex vivo. [18F]FEPPA brain uptake by PET imaging correlated with disease severity and neuroinflammation. However, TSPO expression by immune cells contributed to significant blood pool [18F]FEPPA activity which could confound [18F]FEPPA-PET imaging results. Conclusions: TSPO is a biologically relevant imaging target for ZIKV neuroinflammation. Brain [18F]FEPPA uptake can be a surrogate marker for ZIKV disease and may be a potential PET imaging marker for ZIKV-induced neuroinflammation. Future TSPO-PET/SPECT studies on viral neuroinflammation and related encephalitis should assess the contribution of immune cells on TSPO expression and employ appropriate image correction methods to subtract blood pool activity.


  • Open Access

    Peptide-Conjugated Phosphorodiamidate Morpholino Oligomers for In Situ Live-Cell Molecular Imaging of Dengue Virus Replication

    by Carla Bianca Luena Victorio, Wisna Novera, Jing Yang Tham, Satoru Watanabe, Subhash G. Vasudevan, Ann-Marie Chacko

    Current methods to detect and monitor pathogens in biological systems are largely limited by the tradeoffs between spatial context and temporal detail. A new generation of molecular tracking that provides both information simultaneously involves in situ detection coupled with non-invasive imaging. An example is antisense imaging that uses antisense oligonucleotide probes complementary to a target nucleotide sequence. In this study, we explored the potential of repurposing antisense oligonucleotides initially developed as antiviral therapeutics as molecular probes for imaging of viral infections in vitro and in vivo. We employed nuclease-resistant phosphorodiamidate synthetic oligonucleotides conjugated with cell-penetrating peptides (i.e., PPMOs) previously established as antivirals for dengue virus serotype-2 (DENV2). As proof of concept, and before further development for preclinical testing, we evaluated its validity as in situ molecular imaging probe for tracking cellular DENV2 infection using live-cell fluorescence imaging. Although the PPMO was designed to specifically target the DENV2 genome, it was unsuitable as in situ molecular imaging probe. This study details our evaluation of the PPMOs to assess specific and sensitive molecular imaging of DENV2 infection and tells a cautionary tale for those exploring antisense oligonucleotides as probes for non-invasive imaging and monitoring of pathogen infections in experimental animal models.


  • The Saffold Virus-Penang 2B and 3C Proteins, but not the L Protein, Induce Apoptosis in HEp-2 and Vero Cells

    by Yishi Xu, Carla Bianca Luena Victorio, Tao Meng, Qiang Jia, Yee-Joo Tan, Kaw Bing Chua